🔗 Permalink

Inventor profile of:

Howard E. Gendelman

City:

Omaha, Nebraska

Country:

United States

Published Applications:

Last publication date:

2026-03-12

Top Assignees for applications by Howard E. Gendelman

The entities that hold a legal rights for patent applications filed by inventor Gendelman Howard E.:

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 17 Lincoln, NE United States
Temple University of the Commonwealth System of Higher Education 2 Philadelphia, PA United States
The University of Rochester 1 Rochester, NY United States
THE SCRIPPS RESEARCH INSTITUTE 1 Jolla, CA United States
The Board of Regents of the University of Nebraska 1 Omaha, NE United States
BAXTER HEALTHCARE S.A. 1 Glattpark (Opfikon), Switzerland
BAXTER INTERNATIONAL INC. 1 Deerfield, IL United States

Recent patent applications by Gendelman Howard E.

Howard E. Gendelman from Omaha, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-03-12

US20260069698A1

Human necessities

ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF

#2 | 2026-02-26

US20260053892A1

Human necessities

Induction and Expansion of Regulatory T Cells

#3 | 2025-11-27

US20250360083A1

Human necessities

LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF

#4 | 2024-05-23

US20240165266A1

Human necessities

LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF

#5 | 2024-05-02

US20240139310A1

Human necessities

MICROPARTICLE COMPOSITIONS AND METHODS USE THEREOF

#6 | 2024-03-28

US20240100171A1

Human necessities

Antiviral prodrugs and nanoformulations thereof

#7 | 2022-07-07

US20220211714A1

Human necessities

COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTICS

#8 | 2022-06-23

US20220194990A1

Chemistry; metallurgy

VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF

#9 | 2022-03-24

US20220091111A1

Physics

METHODS AND COMPOSITIONS FOR DIAGNOSING NEURODEGENERATIVE DISEASE

#10 | 2021-04-22

US20210113558A1

Human necessities

Antiviral prodrugs and formulations thereof

#11 | 2021-03-04

US20210060138A1

Human necessities

CRISPR and LASER ART Eliminates HIV

#12 | 2020-12-17

US20200390796A1

Human necessities

Antiviral prodrugs and formulations thereof

#13 | 2020-05-07

US20200140865A1

Chemistry; metallurgy

AN HIV-1 ERADICATION STRATEGY EMPLOYING NANOFORMULATED ANTI-RETROVIRAL DRUGS AND GENE EDITING AGENTS

#14 | 2019-04-25

US20190117735A1

Human necessities

Biomarkers for monitoring immune transformation

#15 | 2018-02-01

US20180028457A1

Human necessities

Compositions and Methods for the Delivery of Therapeutics

#16 | 2017-10-26

US20170304308A1

Human necessities

Compositions and methods for the delivery of therapeutics

#17 | 2017-06-15

US20170165271A1

Human necessities

Compositions and Methods for the Delivery of Therapeutics

#18 | 2016-12-01

US20160346222A1

Human necessities

Compositions and methods for the delivery of therapeutics

#19 | 2016-06-30

US20160184417A1

Human necessities

Methods and compositions for inhibiting diseases of the central nervous system

#20 | 2016-05-19

US20160136105A1

Human necessities

Compositions and Methods for the Delivery of Therapeutics

#21 | 2015-10-22

US20150297587A1

Human necessities

Mixed lineage kinase inhibitors for HIV/AIDS therapies

#22 | 2015-05-21

US20150139937A1

Human necessities

Methods and compositions for inhibiting diseases of the central nervous system

#23 | 2015-05-07

US20150125401A1

Human necessities

SMALL MAGNETITE THERAPEUTICS AND METHODS OF USE THEREOF

#24 | 2015-03-19

US20150079007A1

Human necessities

TUNABLE MULTIMODAL NANOPARTICLES AND METHODS OF USE THEREOF

#25 | 2014-11-27

US20140349877A1

Physics

Method for diagnosing and treating Parkinson's disease via measurment of effector memory t-cells

#26 | 2014-01-02

US20140004148A1

Human necessities

Methods and compositions for inhibiting diseases of the central nervous system

#27 | 2013-09-12

US20130236553A1

Human necessities

Compositions and Methods for the Delivery of Therapeutics

#28 | 2010-02-04

US20100028320A1

Human necessities

Methods and compositions for inhibiting diseases of the central nervous system

#29 | 2006-12-14

US20060280430A1

Human necessities

Method for delivering particulate drugs to tissues

#30 | 2005-06-16

US20050130128A1

Chemistry; metallurgy

Antibodies specific for NEBR1 and methods of use thereof

InventorID:

432998 ⎘